CMF for breast Ca does make a difference

April 15, 2005

Adjuvant treatment with cyclophosphamide, methotrexate, and fluorouracil (CMF) in women with operable breast cancer at risk of relapse halves that threat and reduces the risk of death with minimal long-term sequelae.

Adjuvant treatment with cyclophosphamide, methotrexate, and fluorouracil (CMF) in women with operable breast cancer at risk of relapse halves that threat and reduces the risk of death with minimal long-term sequelae.

Italian researchers conducted a cohort study in which they reviewed nearly 30 years' worth of data from three randomized controlled studies and one observational study conducted previously at the Istituto Nazionale Tumori in Milan.

They found that the adjuvant treatment regimen reduced the relative risk of relapse significantly (hazard ratio 0.71, 95% CI; 0.56-0.91, P=0.005), as well as the risk of death (0.79, 0.63-0.98, P=0.04). They found six cycles to be sufficient, with no additional benefit conferred by 12.